- Open Access
Implanted subcutaneous versus intraperitoneal bioscaffold seeded with hepatocyte-like cells: functional evaluation
Stem Cell Research & Therapy volume 12, Article number: 441 (2021)
Background and objectives
The X-linked bleeding disorder, hemophilia A, is caused by defective production of factor VIII (FVIII). Hemophilic patients require regular FVIII infusions. Recombinant factor replacement poses the safest line of therapy. However, its main drawbacks are high expenses and the higher liability for formation of inhibitors. Recent studies confirmed the ability of bone marrow-derived stem cells to secrete FVIII. This study aims to generate bioscaffold from decellularized liver and subsequently seed it with trans-differentiated human stem cells into hepatic-like cells. This scaffold can then be implanted intraperitoneally or subcutaneously to provide FVIII.
After generation of the bioscaffold, seeding of discoid scaffolds with trans-differentiated human hepatocyte-like cells was performed. Then, the generated organoid was implanted into peritoneal cavity or subcutaneous tissue of experimental rats.
Serum human FVIII was significantly increased in rats subjected to subcutaneous implantation compared intraperitoneal implantation. Immunostaining for detecting Cytokeratin 19 and human anti-globulin confirmed the presence of mature human hepatocytes that were significantly increased in subcutaneous implanted scaffold compared to the intraperitoneal one.
Implantation of decellularized bioscaffold seeded with trans-differentiated stem cells in rats was successful to establish production of FVIII. Subcutaneous implantation showed higher FVIII levels than intraperitoneal implantation.
Hemophilia is an x-linked inherited disease caused by deficiency of clotting factors VIII (Hemophilia A) or IX (Hemophilia B). Hemophilia is associated with recurrent and spontaneous bleeding, mainly internal bleedings into joints or muscles . Hemophilia A occurs in 1 out of 10,000 male births, whereas hemophilia B occurs in 1 out of 30,000 male births. The prevalence of hemophilia A changes with the reporting country, ranging from 5.4 to 14.5 cases per 100,000 male individuals .
Management of Hemophilia A is directed mainly toward symptomatic prevention of bleeding through replacement of defective factor. Several clotting factor VIII concentrates are available for managing hemophilia A. Biotechnology is able to develop recombinant factor concentrates for replacement therapy .
However, the disadvantages of replacement therapy are its high cost, life-long dependence as well as antibody production . The most serious complication of replacement therapy in hemophilia is antibody production . These antibodies are polyclonal high-affinity immunoglobulin G directed against the factor VIII protein leading to an increase in the management cost, morbidity and mortality .
Increasing circulating level of factor VIII by 1–5% could substantially reduce bleeding tending. Being the source of plasma factor VIII, liver cells became the main hope for treating hemophilia A . Moreover, to find a feasible long-life line of treatment such as liver cell based therapy emphasizes a major concern. Recently, Rossi and colleagues have reported improvement viability and functions of transplanted hepatocytes seeded onto naturally developed bioscaffold by decellularization process .
The formed bioscaffold is composed of hepatic-extracellular matrix (ECM) such as collagen, elastin and proteoglycans, and no remaining functioning cells, but still rich in factors that could promote cellular interaction, growth and survival . Thus, seeding the decellularized liver bioscaffold with stem cells can enhance their growth, therapeutic efficacy and differentiation into functioning cells 
Mesenchymal stem cells (MSCs) represent a feasible cell source for cell therapy for their accessibility, expansion potential, high regenerative capacity, and safety in a large number of clinical trials . Previous studies revealed that MSC-derived from different sources (both mice and humans) can be differentiated into hepatocytes, using various protocols and techniques in vitro .
Notably, this study was designed to evaluate the function and histology of decellularized liver bioscaffold seeded with MSC-derived hepatocyte-like cells implanted in rats and compare between subcutaneous and intraperitoneal routes, finally to verify the ability of both scaffolds to survive, function and secrete functional proteins.
Materials and methods
Generation of bioscaffold
Surgical procedure: Animals were euthanized, then a longitudinal anterior abdominal incision was made. A 5-kg piglet liver was removed surgically following intraoperative ligation of the hepatic artery and splenic vein to avoid leakage of the detergents used in decellularization process. The liver was dissected with the capsule intact.
The liver was dissected and the portal vein was cannulated and connected to pump that perfused the liver with sterile distilled water. 15 L of distilled water was injected in the liver until all blood inside the liver was washed. Subsequently, 6 L of detergent were injected (1% SDS + 0.1% ammonium hydroxide, Sigma Aldrich, St. Louis, USA) to kill the hepatocytes and the endothelial cells. Decellularized liver bioscaffolds were detected by being transparent then confirmed laboratory by the absence of positive staining for hematoxylin  of liver sample.
Mononuclear cell separation from human bone marrow samples
The experiments involving humans were carried out in accordance with The Code of Ethics of the World Medical Association (Human Declaration of Helsinki). After institutional ethical committee approval and taking informed consent from the participants, three-milliliter of bone marrow was obtained by aspiration from the posterior iliac spine. The mononuclear cells were obtained from fresh human bone marrow samples after using Ficoll–Hypaque density gradient (density, 1.077; Biochrom KG, Berlin) . Cell pellets were suspended in 1 mL serum-free DMEM media and counted using a hemocytometer. Counting and viability was assessed by the vital stain trypan blue (0.4%) exclusive dye (Sigma).
Mesenchymal stem cell (MSCs) separation and identification
After isolation, primary culture and subculture of MSCs were done according to Soleimani and Nadir technique . Flasks used were incubated in a horizontal position in humidified incubator at 37 °C and 5% CO2. The first change of media was accomplished at the third to the fifth day to remove non adherent cells, and then the media was changed twice weekly until reaching 70–90% confluency which was assessed by the inverted microscope. The adherent cells were harvested by trypsinization according to Bieback method . After trypsnization, cells were examined under the microscope, counted and the viability was assessed using the trypan blue dye. The cells released from primary culture were divided into two parts, one used for MSCs identification using flow cytometry and the other part for subculture and induction of hepatocyte differentiation. Flow cytometry was done and results were declared as percentage of cells expressing CD 105+, CD 73+ and CD 271+ and negative for CD 45+ and CD 34+ in the gated population of mononuclear cells (Fig. 1).
Induction of hepatocyte differentiation
Induction of hepatocyte differentiation was done according to Li method . At this step, 14 samples were incubated with hepatocyte growth factor (HGF) 20 ng/mL together with fibroblast growth factor (FGF) 10 ng/mL for induction of differentiation, whereas another six samples were used as a control.
Evaluation of hepatocyte differentiation
Evaluation of hepatocyte differentiation was done using several measures firstly under inverted microscope, and dishes were examined for morphological changes denoting differentiation.
Gene expression of AFP and albumin was detected using real time: PCR
The total RNA was extracted from hepatic-like cells according to the manufacture instructions. In brief, the first denaturation step was done by incubating reaction tubes for 10 min at 94 °C, then followed by 40 cycles of 1 min at 94 °C (denaturation). For AFP and albumin, 1 min was applied for 58 °C and 56 °C for β-actin (annealing) and 1 min at 72 °C (extension) and the final elongation step was at 72 °C for 7 min. The primer sequence for AFP is sense; ACCATGAAGTGGGTGGAATC, and antisense; TGGTAGCCAGGTCAGCTAAA, for albumin is sense; GCATCCTGATTACTCTGTCG, and antisense; GTTCACCAAGGATTCTGTGC, and for β-actin is sense; GGGCATGGGTCAGAAGGATT, and antisense; GAGGCGTACAGGGATAGCAC.
On day 14, the media were condensed five times by freeze drying before estimating concentrations of albumin and AFP . Albumin and AFP were also measured in the samples using radioimmunoassay method. AFP was measured using AFP monoclonal antibody (P5B8) a product of ThermoFisher Cat #MA5-14666, and albumin was measured using human serum albumin monoclonal antibody (1E1) a product of TheimoFisher Cat # MIH3001.
Seeding the formed scaffolds with differentiated MSCs
The differentiated MSCs were resuspended at a concentration of 2 × 106/50 μL/cubic scaffold. Using a 0.5 mL insulin syringe, cells were drawn up then released drop by drop over scaffolds to cover the prepared decellularized tissue.
Animal experimental design
All animal experiments complied with the ARRIVE guidelines and carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments. This study was conducted on 21 adult male albino rats with average body weight 200 g, purchased from and housed in the Animal House, Faculty of Medicine, Cairo University, and experimental procedures were done in Physiology laboratory, Faculty of medicine according to the guidelines for the care and use of experimental animals of Cairo University and were divided into the following three groups: Group I (control): It included seven rats that were left without any intervention. Group II (subcutaneous group): It included seven rats that were implanted subcutaneously with the generated bioscaffold after differentiation in culture for14 days. Group III (Intraperitoneal group): It included seven rats that were implanted intraperitoneally with the generated bioscaffold after differentiation in culture for 14 days.
By the end of the study (after 10 days), blood samples were collected and plasma was separated for detecting level of FVIII using human FVIII ELISA kit (total FVIII antigen) (ab272771). The detection method was colorimetric. Rats of all groups were sacrificed after 10 days. The rats were sacrificed by cervical dislocation. Skin and peritoneal specimens were fixed in 10% formol saline for 24 h. Paraffin blocks were prepared and 5-μm-thick serial sections were subjected to the following studies in the Histology Department, Faculty of Medicine, Cairo University:
After preparation of paraffin blocks, serial sections from all studied groups were stained with; 1-Hematoxylin and eosin (H&E) 2-Immunohistochemical Study: using the following: a-Alpha-fetoprotein (AFP), (catalog # MBS173005) MyBioSource company, Southern California, San Diego, USA) for early progenitor stem cells. b-Cytokeratin 19, (Mouse Anti-CK19 antibody), purchased from Biological life science Company, USA (Catalog # 381146), for detecting oval cell which is bipotent, can differentiate for hepatocyte and cholangiocyte. 3-Human anti-globulin (HAG), rabbit Anti-Human IgG antibody (ab98568, Cambridge, UK), for detecting of mature human hepatocytes.
Computer-assisted image analysis was performed using Olympus camera connected to Olympus microscope, using interactive measurements menu. The assessment of area percent (%) of AFP, CK19 (in both culture tissue and experimental groups) &HAG was measured using binary mode. The measurements were done within 10 non-overlapping fields of each specimen using × 100 magnification.
Statistical analysis and calculations were performed using Statistical Package for the Social Sciences (SPSS) version 16. The comparison between the different groups was analyzed using ANOVA test, followed by Bonferroni post hoc test to detect which pairs of groups caused the significant difference. P values < 0.05 were considered statistically significant.
Bioscaffold quality control and characterization
Enhanced production of human factor VIII with implantation of bioscaffolds: Therapeutic potential of implanted bioscaffolds documented production of human factor VIII in group II and III. However, serum level of HF VIII was significantly increased in rats subjected to subcutaneous compared to animals received bioscaffold by intraperitoneal implantation (Fig. 2).
Cell morphology presenting differentiation of MSCs
Differentiation of human mesenchymal stem cells to hepatic phenotype was confirmed by inverted microscope (Fig. 3).
Examinations of cellular differentiation for detection of differentiated hepatocyte-like cells of the culture scaffold was done using H&E and immunohistochemical stains for both alpha-fetoprotein (AFP) and cytokeratin 19 (CK19). Results showed on day 0 no differentiated cells detected, on day 7 increased numbers of differentiated cells and on day 14 the cells increased in H&E and in CK19 while decreased in AFP immunostaining (Fig. 4).
Estimation of albumin and AFP secretion in culture media
Data confirmed successful induction of differentiation of human bone marrow mesenchymal stem cells (HBMSCs). That was reflected on significant increase in mean value of both albumin (1.06 ± 0.03 µg/mL) and AFP (20.8 ± 0.94 µg/mL) in culture media of differentiated stem cells compared to the mean values of albumin (0.2 ± 0.01 µg/mL) and in AFP (12.93 ± 0.62 µg/mL) estimated in culture media of the control undifferentiated cells.
Examination of skin sections from Group I (control group) showed in H&E-stained sections normal epidermal and dermal layer with normal hair follicles and thin keratin layer while showed in immunostained sections −ve skin reaction. Examinations of skin sections from Group II (subcutaneous group) showed in H&E-stained sections hepatocyte-like cells at the bases of the hair follicles. In sections, stained with AFP showed +ve immunostaining cells detected at the roots of hair follicles. While in sections stained with CK19 showed +ve immunostaining cells detected at the shafts of hair follicles (Fig. 5). Examinations of intraperitoneal sections from Group I (control group) showed in H&E-stained sections normal intraperitoneal tissue with some adipose cells and some muscle fibers within loose CT layer while in immunostained sections showed −ve intraperitoneal reactions. Examinations of H&E-stained sections from Group III (intraperitoneal group) showed hepatocytes-like cells at the scaffold with the dilated blood vessel. In both sections stained with AFP and with CK19 showed +ve immunostaining cells detected at the scaffold (Fig. 6). Examinations of sections stained with HAG showed in Group II (subcutaneous group) +ve immunostained cells detected at the shaft of hair follicle and Group III (intraperitoneal group) showed +ve cells detected at the scaffold and blood vessels (Fig. 7).
On day 14, culture tissue showed a significant decrease in the mean area% of AFP immune positive cells and a significant increase in the mean area% of CK19 immuno +ve cells as compared to day 7 (Table 1).
Mean area% of AFP +ve cells, area% of CK19 and area% of HAG +ve cells immune-expression in control and experimental groups showed statistically significant increased compared to the group I. Group II showed a significant decrease in the mean area% of AFP and a significant increase in area% of CK19 and in area% of HAG +ve cells as compared to group III (Table 2).
Enhanced production of human factor VIII with implantation of bioscaffolds
Therapeutic potential of implanted bioscaffolds documented production of human factor VIII in group II and III. However, serum level of HF VIII was significantly increased in rats subjected to subcutaneous compared to animals received bioscaffold by intraperitoneal implantation (Fig. 2).
The biologically developed scaffolds from animal organs by the process of decellularization can be used to generate a transplantable fully functioning organ . In the present work, we used decellularized pig liver as a bioscaffold for transplantation of hepatocyte-like cells (HLCs) differentiated from human bone marrow mesenchymal stem cells (MSCs). The concept of using decellularized scaffolds was explained by Uygun et al.  who stated, these scaffolds can provide a 3D environment helping cell attachment, proliferation, and promotes its function. In our work, the transplanted HLCs were capable of achieving their function in vivo by secreting human factor VIII that was detected in serum samples of the experimental rats.
It was reported that human MSCs from bone marrow, umbilical cord blood, adipose tissues, and fetal bone marrow can differentiate to HLCs . The benefits of MSCs were clarified by Croce et al.  who mentioned that MSCs are known by simple isolation, high proliferation abilities and can differentiate into HLCs under proper culture conditions in vitro.
Hepatocyte-like cells derived from bone marrow MSCs have the potential to overcome the limitations of primary human hepatocytes for clinical application in treating liver diseases  such as the quality and variability of their metabolic/functional activity. Even more, hepatocytes can’t be easily maintained in culture for extended time .
Growth factors can selectively alter cell function and promote MSC proliferation, migration, and differentiation. Accordingly, researchers have tested different protocols to differentiate these cells into other cell types such as hepatocytes. Different growth factors and cytokines are used for sequential differentiation such as FGF, HGF, oncostatin M, and dexamethasone .
In the present study, HBMSCs were isolated, cultured and then differentiated into HLCs. On day 14 of the culture, the differentiated cells showed a significant increase in the level of AFP and albumin in the culture media as compared to the control (undifferentiated cells).These results were in accordance to previous Study which confirmed hepatic differentiation by AFP and albumin level .
During differentiation, the morphology of HBMSCs changed and the cells expressed hepatocyte-specific antigens as AFP (immature marker) which increased on day 7 and decreased gradually on day 14, on contrary CK19 (mature marker) decreased on day 7 and increased gradually on day 14.These findings agreed with previous work reported that, AFP is an immature marker and albumin synthesis is a mature marker for hepatocytes . Improvement of liver cyto-architecture is indicted by increasing the expression of albumin and reduced the level of AFP . This is consistent with the fact that AFP is expressed in endoderm and in fetal hepatocytes and that after birth the AFP gene is selectively silenced . CK19 is a marker for hepatic oval cell which is a bipotent progenitor cell that can differentiate into both mature hepatocytes and bile duct epithelial cells .
In this study, the clusters of HLCs in the decellularized liver scaffold were implanted subcutaneously (group II) and intraperitoneally (group III). The subcutaneous implantation of the decellularized scaffold presented good histocompatibility . In subcutaneous implantation, there are a few concerns regarding implantation such as degradation and inflammation .
Implantation of biomaterials stimulates the host immune reaction and enhances recruitment of macrophages that could be attracted by the local bulk of pro-inflammatory cytokines and growth factors allowing monocyte infiltration. The activated immune system release of pro-fibrogenic factors that recruit fibroblasts leading to the final outcome of fibrotic deposition and compromising functions of the implant . In addition, other studies demonstrated stimulation of inflammatory and immune responses after implantation of acellular scaffolds in animal models. The decellularization approaches induce elimination of antigenic parts of the tissues such as the nucleus and other structural elements. However, the extracellular matrix component of the scaffold could stimulate the host immune response, [30, 31] causing accumulation of myofibroblasts leading eventually to fibrosis .
Moreover, the peritoneal membranes are covered by mesothelial cells that have the ability of mesothelial-to-mesenchymal transition, which is a type of extracellular matrix. The latter contributes to development of peritoneal fibrosis upon chronic irritation [32, 33]. Thus, it may weaken therapeutic efficacy of intraperitoneal implant.
Decellularization strategy for synthesis of bioscaffold seeded with hepatocyte-like cells has the potential to present an alternative for recombinant factor VIII replacement to treat hemophilia patient. Increased mean values of serum FVIII in groups subjected to subcutaneous implantation make subcutaneous more preferable than intraperitoneal one.
Availability of data and material
The data that support the findings of this study are available from the corresponding author on reasonable request.
Mesenchymal stem cells
Hepatocyte growth factor
Fibroblast growth factor
Human bone marrow mesenchymal stem cells
Christian Q, Sørensen LQ, Tait RC, de Moerloose P, Holme PA. Macroscopic hematuria as a risk factor for hypertension in ageing people with hemophilia and a family history of hypertension. Medicine. 2020;99(9):e19339.
Kumar S, Sinha S, Bharti A, Meena LP, Gupta V, Shukla J. A study to determine the prevalence, clinical profile and incidence of formation of inhibitors in patients of hemophilia in North Eastern part of India. J Family Med Prim Care. 2019;8:2463–7.
Boban A, Hermans C. An evaluation of the safety and efficacy of turoctocogalfa for hemophilia A. Expert Rev Hematol. 2020;13:303–31.
Tatsumi K, Okano T. Hepatocyte transplantation: cell sheet technology for liver cell transplantation. Curr Transpl Rep. 2017;4:184–92.
Schep SJ, Boes M, Schutgens REG, van Vulpen LFD. An update on the ‘danger theory’ in inhibitor development in haemophilia A. Expert Rev Hematol. 2019;12:335–44.
Ghosh K, Shukla R. Future of haemophilia research in India. Indian J Hematol Blood Transfus. 2017;33:451–2.
Rossi EA, Quintanilha LF, Nonaka CKV, Souza BSF. Advances in hepatic tissue bioengineering with decellularized liver bioscaffold. Stem Cells Int. 2019;2019:2693189.
Pei M, Li JT, Shoukry M, Zhang Y. A review of decellularized stem cell matrix: a novel cell expansion system for cartilage tissue engineering. Eur Cell Mater. 2011;22:333–43.
Orge ID, Gadd VL, Barouh JL, Rossi EA, Carvalho RH, Smith I, Allahdadi KJ, Paredes BD, Silva DN, Damasceno PKF, Sampaio GL, Forbes SJ, Soares MBS, Souza BSF. Phenotype instability of hepatocyte-like cells produced by direct reprogramming of mesenchymal stromal cells. Stem Cell Res Ther. 2020;11:154–68.
Afshari A, Shamdani S, Uzan G, Naserian S, Azarpira N. Different approaches for transformation of mesenchymal stem cells into hepatocyte-like cells. Stem Cell Res Ther. 2020;11:54–67.
Rossi EA, Quintanilha LF, Nonaka CK, Souza BS. Advances in hepatic tissue bioengineering with decellularized liver Bioscaffold. Stem Cells Int. 2019;2019:1–11.
Gabr H, Zayed R, El-Beshlawy A, Hegazy L, Fawzy R, Samir M, Hanaa H. Differentiation of bone marrow hematopoietic stem cells into FVIII-producing hepatocytes: approach to hemophilia treatment. Comp Clin Pathol. 2014;23:193–8.
Soleimani M, Nadri S. A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc. 2009;4(1):102–6.
Bieback K, Kern S, Klüter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells. 2008;22:625–34.
Li WC, Ralphs KL, Tosh D. Isolation and culture of adult mouse hepatocytes, methods. Mol Biol. 2010;633:185–96.
Kang XQ, Zang WJ, Bao LJ, Li DL, Song TS, Xu XL, Yu XJ. Fibroblast growth factor-4 and hepatocyte growth factor induce differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocytes. World J Gastroenterol. 2005;11:7461–5.
Uygun BE, Soto-Gutierrez A, Yagi H, et al. Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat Med. 2010;16(7):814–20.
Palakkan AA, Drummond R, Anderson RA, Greenhough S, Tv K, Hay DC, Ross JA. Polarisation and functional characterisation of hepatocytes derived from human embryonic and mesenchymal stem cells. Biomed Rep. 2015;3:626–36.
Croce S, Peloso A, Zoro T, Avanzini MA, Cobianchi L. A hepatic scaffold from decellularized liver tissue: food for thought. Biomolecules. 2019;9(12):813–23.
Shi D, Xin J, Lu Y, Ding W, Jiang J, Zhou Q, Sun S, Guo B, Zhou X, Li J. Transcriptome profiling reveals distinct phenotype of human bone marrow mesenchymal stem cell-derived hepatocyte-like cells. Int J Med Sci. 2020;17:263–73.
Yu Y, Fisher JE, Lillegard JB, Rodysill B, Amiot B, Nyberg SL. Cell therapies for liver diseases. Liver Transpl. 2012;18(1):9–21.
Torizal FG, Kimura K, Horiguchi I, Sakai Y. Size-dependent hepatic differentiation of human induced pluripotent stem cells spheroid in suspension culture. Regen Ther. 2019;12:66–73.
Nakai S, Shibata I, Shitamichi T, Yamaguchi H, Takagi N, Inoue T, et al. Collagen vitrigel promotes hepatocytic differentiation of induced pluripotent stem cells into functional hepatocyte-like cells. Biol Open. 2019;8:1–12.
Varaa N, Azandeh S, Khorsandi L, BijanNejad D, Bayati V, Bahreini A. Ameliorating effect of encapsulated hepatocyte-like cells derived from umbilical cord in high mannuronic alginate scaffolds on acute liver failure in rats. Iran J Basic Med Sci. 2018;21:928–35.
Ma X, Duan Y, Jung CJ, et al. The differentiation of hepatocyte-like cells from monkey embryonic stem cells. Cloning Stem Cells. 2008;10(4):485–93.
Than NN, Newsome PN. Stem cells for liver regeneration. QJM Int J Med. 2014;107:417–21.
Xiang JX, Zheng XL, Gao R, Wu WQ, Zhu XL, Li JH, Yi LV. Liver regeneration using decellularized splenic scaffold: a novel approach in tissue engineering. Hepato-biliary Pancreat Dis Int. 2015;14:502–8.
Khorramirouz R, Go JL, Noble C, Jana S, Maxson E, Lerman A, Melissa D, Young MD. A novel surgical technique for a rat subcutaneous implantation of a tissue engineered scaffold. Acta Histochem. 2018;120:282–91.
Mariani E, Lisignoli G, Borzì RM, Pulsatelli L. Biomaterials: Foreign bodies or tuners for the immune response? Int J Mol Sci. 2019;20(3):636–47.
Iwai S, Torikai K, Coppin CM, Sawa Y. Minimally immunogenic decellularized porcine valve provides in situ recellularization as a stentless bioprosthetic valve. J Artif Organs. 2007;10:29–35.
Wong ML, Griffiths LG. Immunogenicity in xenogeneic scaffold generation: antigen removal vs. decellularization. Acta Biomater. 2014;10(5):1806–16.
Horejs CM, St-Pierre JP, Ojala J, et al. Preventing tissue fibrosis by local biomaterials interfacing of specific cryptic extracellular matrix information. Nat Commun. 2017;8:15509–19.
Gordillo CH, Sandoval P, Muñoz-Hernández P, Pascual-Antón L, López-Cabrera M, Jiménez-Heffernan JA. Mesothelial-to-mesenchymal transition contributes to the generation of carcinoma-associated fibroblasts in locally advanced primary colorectal carcinomas. Cancers (Basel). 2020;12(2):499–509.
We are grateful to Animal House, Faculty of Medicine, Cairo University for providing animals.
The current work received no external fund.
Ethics approval and consent to participate
The work conducted on human was approved by Institutional ethical committee from department of clinical pathology, faculty of medicine, Cairo University. After approval of the current protocol an informed consent was taken from the participants. All animal experiments were approved by institutional ethical committee of histology department and research committee of physiology department faculty of medicine, Cairo University.
Consent for publication
The authors have approved the final article and declared no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Fares, A.E., Gabr, H., ShamsEldeen, A.M. et al. Implanted subcutaneous versus intraperitoneal bioscaffold seeded with hepatocyte-like cells: functional evaluation. Stem Cell Res Ther 12, 441 (2021). https://doi.org/10.1186/s13287-021-02531-2
- Hemophilia A
- Stem cells
- Factor VIII